Media stories about Affymetrix (NASDAQ:AFFX) have been trending somewhat positive on Friday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Affymetrix earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the scientific and technical instruments company an impact score of 45.0356540038606 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Affymetrix (NASDAQ AFFX) opened at $14.01 on Friday. Affymetrix has a fifty-two week low of $8.28 and a fifty-two week high of $16.15.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Affymetrix (AFFX) Stock Price” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-affymetrix-affx-stock-price/1764726.html.

About Affymetrix

Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.

Insider Buying and Selling by Quarter for Affymetrix (NASDAQ:AFFX)

Receive News & Ratings for Affymetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix and related companies with MarketBeat.com's FREE daily email newsletter.